Hirano I
Northwestern University Medical School, Division of Gastroenterology and Hepatology, Searle 10-563, 303 East Chicago Avenue, Chicago, IL 60611, USA.
Curr Gastroenterol Rep. 1999 Jun;1(3):198-202. doi: 10.1007/s11894-999-0034-2.
Achalasia is a rare but important condition affecting the myenteric neurons of the esophagus. A number of studies have provided evidence for the preservation of cholinergic innervation to the esophagus in achalasia. This forms the rationale for the treatment of achalasia with botulinum toxin. Identification of nitric oxide as the primary inhibitory neurotransmitter of the gastrointestinal tract has improved our understanding of the pathophysiology of primary achalasia. Neurons containing nitric oxide are absent within the myenteric plexuses of patients with achalasia, and the experimental inhibition of nitric oxide produces a picture that manometrically mimics achalasia. Recent advances have provided insights into the genetic basis and pathogenesis of a growing number of secondary forms of achalasia. Examples of such secondary disorders include Allgrove's syndrome, autoimmune polyglandular syndrome, and multiple endocrine neoplasia type 2B.
贲门失弛缓症是一种罕见但重要的疾病,影响食管的肌间神经元。多项研究为贲门失弛缓症患者食管胆碱能神经支配的保留提供了证据。这构成了用肉毒杆菌毒素治疗贲门失弛缓症的理论基础。一氧化氮作为胃肠道主要抑制性神经递质的发现,增进了我们对原发性贲门失弛缓症病理生理学的理解。贲门失弛缓症患者的肌间神经丛中缺乏含一氧化氮的神经元,实验性抑制一氧化氮会产生一种在测压上模拟贲门失弛缓症的表现。最近的进展使我们对越来越多继发性贲门失弛缓症的遗传基础和发病机制有了深入了解。此类继发性疾病的例子包括阿尔格罗夫综合征、自身免疫性多内分泌腺综合征和2B型多发性内分泌肿瘤。